相关实验视频

Updated: May 21, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

添加剂奥比努图祖马布在与瑞图西马布抗药的膜性脏病中实现了高缓解率

Huixian Li, Li Jin, Xinfang Xie

American journal of nephrology

|May 19, 2025

概括

奥比努图祖马布在对瑞图西马布耐药的患者治疗膜性病 (MN) 方面表现有前途. 这项研究发现了高缓解率,这表明它是耐火性MN的可行替代疗法.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

膜性脏病 (MN) 经常用Rituximab治疗,但很大一部分患者没有反应.
在MN中抗Rituximab的耐药性需要探索替代治疗策略.

研究的目的:

为了评估obinutuzumab在患有Rituximab耐火性膜性脏病 (MN) 的患者中的疗效.
评估在Rituximab失败后接受Obinutuzumab治疗的MN患者的临床和免疫结果.

主要方法:

一个案例系列研究涉及17名患有脂酶A2受体 (PLA2R) 相关的MN耐药的患者.
患者接受了obinutuzumab,并在治疗前后监测临床/实验室参数.

主要成果:

观察到高缓解率:52.9%的完全缓解和41.2%的部分缓解,平均随访时间为12.6个月.
在6个月后,70.6%的患者实现了缓解,其中12名患者中有11名达到免疫缓解.
在患有性综合征的患者中,治疗有效改善蛋白尿和血清白蛋白水平.

结论:

奥比努图祖马布是MN患者的潜在替代疗法,MN患者对rituximab耐药.
需要进行更大规模的前性研究来证实这些发现,并确定奥比努图祖马布在MN治疗中的作用.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...